Form D · Biotechnology

Transition Bio, Inc.

Cambridge, MA · CIK 0001920890

Offering snapshot reported Oct 25, 2024 · SEC filing

Reported sold
$13.3M
Offering amount: $21.3M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 11, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 25, 2024Initial$13,265,426No comparison8SEC filing
Jan 10, 2024Initial$6,000,000No comparison5SEC filing
Mar 7, 2023Amendment$39,086,000$8,530,025vs Apr 8, 202222SEC filing
Apr 8, 2022Initial$30,555,975No comparison23SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-527791

Source: Form D, filed Oct 25, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Samuel Cohen Director
Shaan Gandhi Director
Tuomas Knowles Director
Martin Kulander Executive
Paxton Major Director
Preet Makkar Executive
George Martin Director, Executive
Connor Mc Dermott Director
Gregory L. Miller Director, Executive
Al Sandrock Director
Stephanie Torruella Executive
Robert Weeks Director
Kathy Yi Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
One Mifflin Place, Suite 400
Cambridge, MA, 02138